Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock”

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if they should buy more, hold, or sell their position in the stock, and here’s what Cramer had to say in response:

“I like Catalyst Pharmaceuticals. It actually has, by the way, real earnings, and it’s a very inexpensive stock. I think you’ve got a winner.”

A person with stock market data on a laptop. Photo by Anna Nekrashevich on Pexels

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) provides treatments for patients managing rare conditions such as Lambert-Eaton myasthenic syndrome and Duchenne muscular dystrophy. During the episode that aired on March 25, 2025, a caller inquired about the stock and Cramer replied:

“No, I think it’s very good and it’s had a very good year. It’s up more than almost every other drug, any company I follow. Yeah, we did like it. Now remember this [is] still [a] small cap stock and there’s some insider selling, but I do think it’s just a very good situation. We went over that a while ago and it beat the earnings estimates…. They were supposed to earn 55 cents and earned 70 cents. That’s my kind of stock. I think you’re in good shape.”

It should be noted that since the above comment was aired, Catalyst Pharmaceuticals, Inc.’s (NASDAQ:CPRX) stock has declined by around 13%.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.